Cetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cetera Investment Advisers grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 35.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,114 shares of the biopharmaceutical company’s stock after purchasing an additional 11,221 shares during the period. Cetera Investment Advisers’ holdings in Catalyst Pharmaceuticals were worth $900,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of CPRX. Castlekeep Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $37,494,000. Bank of America Corp DE increased its stake in shares of Catalyst Pharmaceuticals by 139.5% during the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after buying an additional 913,843 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Catalyst Pharmaceuticals by 1.9% during the fourth quarter. Ameriprise Financial Inc. now owns 282,834 shares of the biopharmaceutical company’s stock valued at $5,903,000 after buying an additional 5,177 shares during the period. Algert Global LLC increased its stake in shares of Catalyst Pharmaceuticals by 185.2% during the fourth quarter. Algert Global LLC now owns 47,920 shares of the biopharmaceutical company’s stock valued at $1,000,000 after buying an additional 31,115 shares during the period. Finally, PDT Partners LLC increased its stake in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock valued at $431,000 after buying an additional 1,030 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $24.49 on Friday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.16. The stock’s 50-day moving average is $23.53 and its 200 day moving average is $22.56. The company has a market cap of $2.99 billion, a P/E ratio of 20.75, a PEG ratio of 3.31 and a beta of 0.70.

Analyst Ratings Changes

Several brokerages have recently commented on CPRX. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Stephens restated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $32.29.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,630,912.64. This represents a 74.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 351,879 shares of company stock valued at $8,214,815. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.